BioCentury
ARTICLE | Clinical News

CPI-613: Phase I data

February 8, 2016 8:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in 20 patients with metastatic stage IV pancreatic adenocarcinoma showed that IV CPI-613 on days 1 and 3 of each 2-week cycle plus modified fluoroura...